Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "cancer"

1426 News Found

Ascentage Pharma closes US$ 75 million equity investment by Takeda
News | June 24, 2024

Ascentage Pharma closes US$ 75 million equity investment by Takeda

Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO


Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Drug Approval | June 22, 2024

Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC

Second FDA approval for KRAZATI - reinforcing its potential across tumor types


Sumitomo Pharma presents new clinical data on DSP-5336 at the European Hematology Association 2024 Congress
News | June 20, 2024

Sumitomo Pharma presents new clinical data on DSP-5336 at the European Hematology Association 2024 Congress

DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia


Ascentage Pharma aims global license agreement with Takeda for Olverembatinib
News | June 20, 2024

Ascentage Pharma aims global license agreement with Takeda for Olverembatinib

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas


Roche receives FDA clearance on its digital pathology solution for diagnostic use
News | June 20, 2024

Roche receives FDA clearance on its digital pathology solution for diagnostic use

This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions


Cipla EU to invest an additional € 3 million in Ethris
News | June 19, 2024

Cipla EU to invest an additional € 3 million in Ethris

Cipla had earlier invested € 15 million in Ethris in 2022


Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27%
Clinical Trials | June 17, 2024

Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27%

First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting


USFDA approves next-gen TKI Augtyro for treatment of solid tumors
Drug Approval | June 17, 2024

USFDA approves next-gen TKI Augtyro for treatment of solid tumors

Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors


Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network
News | June 15, 2024

Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network

Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network


GSK disagrees with ruling by the Delaware State Court on Zantac (ranitidine) litigation
News | June 06, 2024

GSK disagrees with ruling by the Delaware State Court on Zantac (ranitidine) litigation

Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims